AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease

AbbVie (ABBV) announced that its investigational therapy ABBV-466 showed higher endoscopic remission rates in Crohn's disease patients than either anti-IL-23 or anti-α4β7 monotherapy in a Phase 2a study. The results will be presented at the 2026 UEGW Congress. ABBV-466 demonstrated tissue repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes at Week 24. The study included 300 patients with moderate to severe Crohn's disease.

AbbVie's Phase 2a study of ABBV-466, a dual-targeting therapy for Crohn's disease, showed higher remission rates than its components alone. At Week 12, 30.2% of patients achieved remission, rising to 40.5% by Week 24. The study included 300 patients, many of whom had failed prior therapies. ABBV-466 combines risankizumab and trosunilimab. The stock closed at $285.42 on October 16, 2026, and was down 0.17% in pre-market trading.

AbbVie's Phase 2a study of ABBV-466, a dual-targeting therapy for Crohn's disease, showed higher endoscopic remission rates at Week 24 compared to monotherapies. The treatment demonstrated tissue repair and barrier restoration by Week 12, with further improvements at Week 24. Results will be presented at the 2026 UEGW Congress. The study included 300 patients with moderate-to-severe Crohn's disease.

AbbVie (NYSE: ABBV) announced it will present data on seven oncology assets at the 2026 ESMO Congress. Key findings include Temab-A's 30% ORR in colorectal cancer and 50% ORR in lung cancer, ABBV-706's 56% ORR in SCLC, and ABBV-969's 90% ctDNA reduction in prostate cancer. The company highlights its largest ESMO presence to date, showcasing progress in solid tumor treatments.

AbbVie (ABBV) will present data on seven oncology assets at the 2026 ESMO Congress, highlighting progress in lung, colorectal, ovarian, prostate, and gastric cancers. Key findings include Temab-A's 30% ORR in CRC and 50% ORR in NSCLC, ABBV-706's 56% ORR in SCLC, and ABBV-969's 90% ctDNA reduction in mCRPC. The company aims to showcase its solid tumor portfolio's potential.

AbbVie presented data at ESMO 2026 showing promising results for its investigational cancer drugs. In a 17-patient group, 82% responded to ABBV-706 in small-cell lung cancer. Temab-A showed a 30% ORR in colorectal cancer and 50% in non-small cell lung cancer. ABBV-969 demonstrated molecular responses in prostate cancer. ABBV-1480 achieved a 61.9% ORR in lung cancer. The company highlighted its oncology portfolio's potential in diverse cancer types.